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Abstract
Background: Acinetobacter species are associated with increasing mortality due to emerging drug-resistance.
Pediatric Acinetobacter infections are largely undefined in developed countries and clinical laboratory identification
methods do not reliably differentiate between members of the Acinetobacter calcoaceticus-baumannii complex,
leading to improper identification. Therefore we aimed to determine risk factors for invasive Acinetobacter infections
within an academic, pediatric setting as well as defining microbiologic characteristics of predominant strains.
Methods: Twenty-four invasive Acinetobacter isolates were collected from 2009–2013. Comparative sequence
analysis of the rpoB gene was performed coupled with phenotypic characterization of antibiotic resistance, motility,
biofilm production and clinical correlation.
Results: Affected patients had a median age of 3.5 years, and 71 % had a central catheter infection source. rpoB gene
sequencing revealed a predominance of A. pittii (45.8 %) and A. baumannii (33.3 %) strains. There was increasing
incidence of A. pittii over the study. Two fatalities occurred in the A. pittii group. Seventeen percent of isolates were
multi-drug resistant. A pittii and A. baumannii strains were similar in motility, but A pittii strains had significantly more
biofilm production (P value = 0.018).
Conclusions: A. pittii was the most isolated species highlighting the need for proper species identification. The isolated
strains had limited acute mortality in children, but the occurrence of more multi-drug resistant strains in the future is a
distinct possibility, justifying continued research and accurate species identification.
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Background
Acinetobacter species are Gram-negative coccobacilli
many of which are found in soil and fresh water
throughout our natural habitats [1]. However, certain
Acinetobacter species are frequently isolated increasingly
from healthcare facilities and are concomitantly the
source of many nosocomial infections [1]. Specifically,
A. baumannii, A. pittii, and A. nosocomialis of the Aci-
netobacter calcoaceticus-baumannii (Acb) complex have
become the most medically relevant members of the
genus as they are most frequently isolated from health
care facilities as well as human tissues. Patients with im-
paired host defenses in intensive care unit (ICU) settings
appear to be an at risk group of acquiring Acinetobacter
infections [2]. Despite this knowledge, the infection
source in outbreaks often cannot be determined, leaving
recommendations to prevent future outbreaks limited
[3]. Additionally, in recent years, some Acinetobacter
strains have demonstrated a propensity to acquire resist-
ance to multiple classes of antibiotics, rendering treatment
of such hospitalized patients extremely difficult [4]. Further-
more, in pediatric patients, A. baumannii is thought to be
the most prevalent organism, which is associated with
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bacteremia, ventilator-associated pneumonia, bronchopul-
monary dysplasia, meningitis, and neutropenia [3, 5, 6].
Currently, our knowledge of the clinical impact of Aci-
netobacter infections in the pediatric patient population
in developing countries and countries with suboptimal
infection control resources have been well documented
[2, 3, 7–11]. However, invasive Acinetobacter infections
associated with large pediatric, academic institutes in
developed countries are still poorly defined due to un-
clear risk factors. Recent studies documented risk factors
for invasive infections as catheter insertions, prolonged
use of antibiotics, as well as underlying chronic diseases
[5, 12]. It is not clear if these risk factors are universal in
all hospital settings, including locations outside of inten-
sive care units. Additionally, improvements in bacterial
sequencing, in particular the Acinetobacter rpoB gene,
have allowed us to more accurately identify clinically im-
portant Acinetobacter species [13–15].
Therefore, the purpose of this study was to retrospect-
ively review cases of invasive Acinetobacter infections
occurring within an academic, pediatric setting in a de-
veloped country from a clinical perspective to define
additional risk factors. Furthermore Acinetobacter strains
were sequenced typed and preliminary characterized for
motility and biofilm formation/maintenance. We hy-
pothesized that Acinetobacter infections would be re-
stricted to ICU settings and predominantly comprised of
strains of A. baumannii.
Methods
Study design
The study was an observational review of patients with
invasive Acinetobacter infections correlated with com-
parative sequencing of hyper-variable regions of the rpoB
gene of Acinetobacter isolates. It was reviewed and ap-
proved by the Institutional Review Board of Nationwide
Children’s Hospital (IRB14-00145). As aggregate patient
data was used, individual consent was not obtained. The
review population consisted of pediatric patients at a
single, large, academic, pediatric institution identified
during the years of 2009–2013. Inclusion criteria in-
cluded pediatric patients less than 21 years old with at
least one positive blood, bone, endotracheal, peritoneal,
or cerebrospinal fluid culture result positive for Acineto-
bacter species [all identified as A. baumannii or A.
baumannii complex by the clinical laboratory using
Vitek 2 (bioMerieux, Durham NC) and other phenotypic
methods as needed]. Antimicrobial susceptibility testing
was performed on all isolates via the Vitek 2 using estab-
lished breakpoints [16]. Multi-drug resistant isolates
(MDR) was defined as isolates non-susceptible to ≥ 1
antimicrobial agent in ≥ 3 antimicrobial categories as de-
fined by the joint initiative of the European Centre for
Disease Prevention and Control (ECDC) and the Centers
for Disease Control and Prevention (CDC) [17]. Study
samples represented a convenience sample of existing
isolates available in the clinical laboratory. Patients with
cystic fibrosis respiratory isolates of Acinetobacter were
excluded from the study. Isolates were frozen and stored
at −80 °C.
A comprehensive review of clinical and demographic
patient information was performed surrounding positive
culture identification. Patient demographics included
gender, age, race, county of residence, and insurance
type. Information related to determining the source of
the infection including the patient’s location within the
hospital, source of the culture, and susceptibilities were
recorded. A 48 h time period after cultures were ob-
tained was chosen as an initial analysis point based on
standard hospital time-based culture practices needed
for determining culture results. At this time point anti-
biotic selection by the practitioner might change based
on available antimicrobial susceptibilities. Underlying
diagnoses, co-morbidities, secondhand smoke exposure,
and vital signs were recorded. Laboratory data included
complete blood count with differential, creatinine, liver
function tests, as well as the next 5 culture results for
each patient. C-reactive protein and erythrocyte sedi-
mentation rates were available on less than 20 % of the
cohort and therefore not included. Information regard-
ing the patient’s hospital stay included length of stay,
febrile status, oxygen use, ventilator use, imaging and in-
vasive procedures, and mortality. Antibiotic treatment
including antibiotics given and length taken by the pa-
tient along with antibiotic usage in the past 30 days were
noted. Home medication including the use of chronic
immunosuppressants, antibiotics, and gastric acid sup-
pressants were all recorded.
Comparative sequence analysis of the rpoB gene from
clinical Acinetobacter isolates
Acinetobacter rpoB hyper-variable region sequencing was
performed on Acinetobacter isolates according to a
previously established protocol [18] with the following
modifications. Genomic DNA (gDNA) was prepared from
Acinetobacter isolates utilizing the Gentra Puregene Yeast/
Bact. Kit B (Qiagen) according to the manufacturer’s proto-
col. One hundred nanograms of gDNA from each isolate
were used in a PCR with one of two sets of primers. The
first set of primers, spanning zone 1, were Ac696F (5′-
TAYCGYAAAGAYTTGAAAGAAG-3′) and Ac1093R (5′-
CMACACCYTTGTTMCCRTGA-3′) and the second set
of primers, spanning zone 2, were Ac1055F (5′-GTGATAA
RATGGCBGGTCGT-3′) and Ac1598R (5′-CGBGCRTGC
ATYTTGTCRT-3′).
DreamTaq DNA polymerase (Thermo Scientific) was
used according to manufacturer’s protocol with the fol-
lowing thermocycling conditions: 1 cycle at 95 °C for
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2 min; 30 cycles at 95 °C for 30 s, 55 °C for 30 s, and
72 °C for 1 min; 1 cycle at 72 °C for 10 min. PCR prod-
ucts were purified using the QiaQuick PCR purification
kit (Qiagen) according to the manufacturer’s protocol.
Clean PCR products were verified by electrophoresis
and sent off for sequencing by Eurofins MWG Operon.
Raw sequence files were trimmed and edited using
MegAlign and EditSeq software applications (DNAS-
TAR). Trimmed sequence files for the two hyper-
variable regions of a single isolate were combined into a
single FASTA file for phylogenetic analysis. The com-
bined FASTA files for each isolate, as well the corre-
sponding sequences from the reference Acinetobacter
strains used for phylogenetic analysis, were aligned ini-
tially by the Clustal W method utilizing UPGMB for the
cluster method and the Kmer4-6 method for the dis-
tance measure. Later parameters utilized UPGMB for
the cluster method and the Kimora % identity method
for distance measure. Sequence distances were com-
puted with the metric uncorrected pairwise distance and
assembled into a phylogenetic tree using the MegAlign
Pro software (DNASTAR).
Motility assays
Twitching motility was investigated per previously de-
scribed protocols with the following modifications [19].
Twitching plates contained 10 g tryptone/L and 10 g
agarose/L. Briefly, bacterial strains were grown overnight
and a single colony was used to inoculate each twitching
plate to the bottom of the petri dish with a sterile
wooden applicator stick. Twitching plates were incu-
bated at 37 °C in a humidified incubator for 16 h. To
visualize zones of twitching motility, the agarose was re-
moved, the adherent bacterial population was washed
with phosphate buffered saline, and stained with 0.1 %
crystal in water. Bacteria positively exhibiting twitching
motility were defined by demonstrating a zone of motil-
ity of >10 mm around the site of inoculation. Surface-
associated motility was simultaneously assessed per our
previously published methodologies [19]. Bacteria posi-
tively exhibiting surface-associated motility were defined
as strains with a halo growth zone of >20 mm. Assays
were performed in triplicate.
Crystal violet retention assay
In order to assess the ability of each isolate to form
biofilms, the crystal violet retention assay was performed
as described previously [20] with minor modifications.
Mueller Hinton (MH) broth was inoculated with one
bacterial colony and incubated overnight at 37 °C for ap-
proximately 16–18 h. Cultures were subsequently di-
luted 1:100 in fresh MH broth and 100 μl of diluted
culture was added to each well in 96 well microtiter
plate and incubated overnight at 37 °C. Adherent cells
were washed once with deionized water and stained with
125 μl of 0.1 % crystal violet solution for 15 min at room
temperature and washed 5 times with deionized water.
Subsequently, dye was released from the cells using
200 μl of 95 % ethanol. Absorbance was measured at
595 nm on a Synergy H1 Hybrid Reader spectrophotom-
eter (Biotech, Biotech Instruments, Vermont, USA). The
biofilm data represent the average of three independent
experiments of triplicate wells.
Statistical analysis
All analyses were performed using Stata/MP, version
13.1 or GraphPad Prism version 6.03. For all analyses, a
P value < 0.05 was considered statistically significant.
Descriptive statistics for continuous variables were pre-
sented as medians with 25–75th percentile ranges; and de-
scriptive statistics for categorical variables were presented




Twenty-four isolates reported as A. baumannii from the
clinical microbiology laboratory were recovered during
the study period from 22 separate patients. A phylogen-
etic tree was derived after comparative sequence analysis
of hyper-variable regions of the rpoB gene from Acineto-
bacter isolates using the BioNJ algorithm [21] (Fig. 1).
The isolates were predominately composed of A. pittii
(45.8 %) and A. baumannii (33.3 %). Other identified
strains included one strain of A. calcoaceticus and two
strains of A. nosocomialis. Two isolates, 26702 and
33291 were non-identified species. Both cases of Acine-
tobacter-associated death were caused by A. pittii. Not-
ably, 70.0 % (n = 7) of the isolates in the last 2 years of
the study were also A. pittii, representing a predominant
shift towards A. pittii for the most recent institutional
isolates (30.8 % A. pittii the previous three years com-
bined, n = 4). There were no reported hospital or unit
specific outbreaks of Acinetobacter infection during the
study period.
Subject characteristics
Patient demographics and characteristics are listed in
Table 1. The population was predominantly Caucasian
and had a median age of 3.5 years. Identified risk factors
for systemic infection are listed in Table 1. There was no
consistent underlying primary diagnosis for the patients,
as a total of 17 unique primary conditions were found
for the 22 patients. Nearly 71 % of subjects had an
indwelling central venous catheter source of the first
positive culture with a non-significant increase in sub-
jects with A. pittii (72.7 %) compared to A. baumannii
(62.5 %). Over 40 % of subjects were on chronic
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Fig. 1 Phylogenetic Tree of Acinetobacter Clinical Isolates. Acinetobacter rpoB sequences from our collection as well as reference sequences were
aligned using Clustal Omega based on the BioNJ algorithm. The tree was built using MegAlign Pro from the DNASTAR suite of programs. Horizontal
branch length is a measure of genetic distance
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antibiotics due to an immunosuppressive state at the time
of Acinetobacter culture positivity, with nearly equal use be-
tween A. baumannii (50 %) and A. pittii (45.8 %) species.
Complete data was available for all patients.
Hospital characteristics
Laboratory data and other characteristics relevant to the
patients’ stay in the hospital are listed in Table 2.
Markers of systemic kidney (creatinine) or liver (ALT,
AST) dysfunction were not present for the majority of
patients. Median length of stay for subjects was
10.5 days, with a non-significant increase in length of
stay for A. pittii compared to A. baumannii (13.5 vs
3.5 days, P value = 0.13). Only two patients died during
hospitalization, both with A. pittii infection. There was a
significant increase in oxygen use for patients with A.
pittii isolates compared to A. baumannii (54.5 % vs 0 %,
P value = 0.018). Two-thirds of positive cultures were
obtained in settings outside of the ICU, however 45.5 %
of A. pittii isolates were from an ICU setting compared
to 25.0 % A. baumannii. Median duration of antibiotic
use was 14.0 days, including outpatient completion if
subject discharged from hospital. Almost 80 % of repeat
cultures were negative for Acinetobacter species within
48 h of initiating antibiotics. Antibiotic susceptibility
patterns for the recovered isolates are shown in Table 3
as the percent of susceptible isolates to a given anti-
biotic. 72.7 % of A. pittii isolates were pan-susceptible,
compared to 62.5 % of A. baumannii isolates (P value =
0.99). Additionally, the clinical laboratory designated
17 % (n = 4) of the isolates as MDR at the time of initial
isolation, with three of these four strains from the A.
baumannii group. Tobramycin demonstrated the least
overall resistance (91.7 % strains susceptible, Table 3).
Antibiotic selection for the first 48 h after clinical onset
of infection and the final treatment course are shown in
Table 4. Gentamicin was the most commonly used anti-
biotic for the full treatment course, although a wide
variety of antibiotics were used during the first 48 h after
onset of positive cultures (Additional file 1: Table S1).
Acinetobacter isolate motility
Twitching and surface-associated motility (swarming)
have been shown to be distinct phenotypes for medically
relevant Acinetobacter [19, 22], but have not been de-
scribed for A. pittii. All isolated strains were assessed for
motility characteristics (Fig. 2a). Surface-associated motil-
ity was observed in 63.6 % of the A. pittii strains, and
62.5 % of the A. baumannii strains (P value = 0.99). Twitch-
ing motility was observed in 72.7 % of the A. pittii strains,
and 50 % of the A. baumannii strains (P value = 0.37). Both
phenotypes were present in 45.5 % of the A. pittii strains,
and only 25 % of the A. baumannii, with the four most re-
cently isolated A. pittii strains harboring both phenotypes.
The A. calcoaceticus strain demonstrated twitching, but not
swarming motility.
Biofilm formation
The production of biofilms allow for bacterial persist-
ence and adherence to medical devices and vascular
lines [23]. Because over 70 % of our isolates were associ-
ated with central line infections, we wanted to determine
if there were any differences in the capability of the iso-
lates to form biofilms, which may predispose to local
strain emergence on medical devices. To quantitate Aci-
netobacter strain biofilm capabilities, individual strains
were tested for their ability to adhere to microtiter plates
as determined by crystal violet stain retention. A. pittii
isolates had significantly higher median biofilm production
compared to A. baumannii isolates (Fig. 2b, P value =
0.0071. Furthermore, both A. nosocomialis isolates (#26959,
# 33904) demonstrated an intermediate ability to form bio-
films as determined by crystal violet retention, however, the
A. calcoaceticus isolate (#27693) demonstrated a minimal
ability to form a biofilm (Fig. 2a). Overall, 75 % of all
isolates were able to form biofilms.
Table 1 Patient demographics and identified risk factors for
Acinetobacter infection






Age (years) 3.5 1.0–13.8
Body Mass Index (BMI) 18.0 15.8–21.2
Source
Blood 79.2 %
Peritoneal Fluid 4.2 %
Bone/soft tissue 8.3 %
Respiratory tract 8.3 %
Risk Factors
Previously healthy 0 %








in past 30 days
41.7 %




Gastroesophageal reflux 41.7 %
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Clinical characteristics based on phenotypic expression
After Acinetobacter isolate motility and biofilm formation
studies were performed, isolates were than characterized
for relevant clinical outcomes based on the percentage of
isolates expressing each phenotype (Table 4). There was
no difference in biofilm production between central line-
associated and non-central line-associated isolates (me-
dian absorbance 0.35 vs 0.42, P value = 0.62), although
there was a non-statistically significant increase in non-
biofilm producing isolates associated with central line
infections (85.7 vs 64.7 %, P value = 0.38). However, all
isolates that demonstrated persistent bacteremia at 48 h
were biofilm-producers. Multi-drug resistance was present
in both biofilm and non-biofilm producing isolates, but
MDR isolates were predominantly non-biofilm producers
(42.9 vs 5.9 %, P value = 0.027). Chronic immunosuppres-
sant use was greater in non-biofilm producing isolates,
but this did not reach statistical significance (71.4 vs
29.4 %, P value = 0.06). There was no difference in the re-
quirement for ICU care, secondhand smoke exposure, or
use of proton pump inhibitors for gastroesophageal reflux
based on biofilm formation. There were no discernible
differences between twitching and swarming isolates in
any of the clinical characteristics.
Discussion
Members of the Acinetobacter calcoaceticus-baumannii
complex are regarded as opportunistic human pathogens
of increasing relevance worldwide due in part to the
emergence of multiply-drug resistant strains; however,
the description of pathogenic Acb members other than
A. baumannii remains limited due in part technological
limitations with current clinical laboratory identifica-
tion methods [24]. Although emerging methods such as
Table 3 Antibiotic susceptibility patterns as percentage of susceptible Acinetobacter isolates
All isolates (%, n) A. pittii (%, n) A. baumannii (%, n)
Ceftazidime 79.2, 19 90.1, 10 62.5, 5
Ciprofloxacin 87.5, 21 100, 11 62.5, 5
Gentamicin 83.3, 20 90.1, 10 62.5, 5
Meropenem 87.5, 21 100, 11 62.5, 5
Piperacillin-Tazobactam 87.5, 21 100, 11 62.5, 5
Trimethoprim-sulfamethoxazole 83.3, 20 90.1, 10 75.0, 6
Tobramycin 91.7, 22 100, 11 75.0, 6
Table 2 Patient laboratory parameters and hospital characteristics
All isolates Percent/Median (Range) A. baumannii A. pittii
Laboratory Data
White blood cell (k/mm3) 7.7 (1.6–14.3) 7.7 (1.2–11.0) 6.8 (1.5–20.9)
Hemoglobin (g/dL) 9.2 (7.8–9.9) 9.0 (7.6–9.3) 8.8 (7.8–11.1)
Neutrophils 60.0 % (44.0–76.0) 62.0 % (26.8–76.3) 57.0 % (49.5–69.5)
Creatinine (mg/dL) 0.45 (0.32–0.65) 0.44 (0.37–0.65) 0.35 (0.24–0.65)
ALT (IU/L) 37.5 (18.0–143.3) 13.0 (8.0–18.0) 135.0 (37.5–157.5)
AST (IU/L) 45.5 (38.5–93.5) 39.0 (37.0–41.0) 71.0 (45.0–177.0)
Hospital Visit
Length of stay (days)
Location of positive culture
10.5 (3.3–67.5) 3.5 (1.5–16.3) 13.5 (5.0–82.5)
Intensive care unit (ICU) 33.3 % 25.0 % 45.5 %
Hematology / Oncology unit 33.3 % 37.5 % 36.4 %
Emergency / Outpatient 33.3 % 37.5 % 18.1 %
Oxygen use 33.3 % 0 % 54.5 %
Ventilator use 37.5 % 18.2 % 45.5 %
Mortality 8.3 % 0 % 18.2 %
Antibiotic duration (days) 14.0 (9.3–14.0) 14.0 (10.0–19.0) 14.0 (6.0–14.0)
Follow up culture negativea 79.9 % 87.5 % 81.8 %
aResults of the next bacterial culture within 48 h of antibiotic initiation
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MALDI-ToF analysis may aid in clinical laboratory-
based identification Acb members for the future, these
methods have not become the gold-standard even in
developed countries. In this study we report the
emergence of A. pittii strains from pediatric patients
with invasive infections, along with a relatively low
mortality rate.
Outbreaks of A. pittii have only been previously re-
ported to a low extent and were thought to be rare in
pediatric settings in the United States [5, 8, 9, 25]. This
may be attributed to the fact that most of the common
clinical laboratory identification methods do not reliably
differentiate between members of the Acb; hence, many
publications may in fact be referring to all members of the
Acb when specifically referencing A. baumannii [5, 24].
Importantly, in the documented cases where A. pittii has
been reported, it can be more commonly recovered from
samples than A. baumannii [8], but this is not the case in
all settings. In our isolate collection, there was an emer-
gence of A. pittii over the last two years of the study
period, indicating a shift towards A. pittii over A. bauman-
nii. This finding will require further follow-up due to the
short time-frame of study follow-up. The significant rise
in the number of isolates of A. pittii in a pediatric popula-
tion also signifies a potential new trend to be cognizant of
for clinicians and researchers, due largely to differences in
antibiotic resistance profiles between species. Notably, we
did not see a difference in basic microbiologic characteris-
tics such as surface motility between the A. pittii and A.
baumannii strains. However, the majority of the most




forming (n = 7)
P value Swarming
motility (n = 16)
Non-swarming
motility (n = 8)
P value Twitching
motility (n = 14)
Non-twitching
motility (n = 10)
P value
Age (years) 4.0 (0.4–11.5) 3.0 (2.0–19.0) 0.84 4.5 (1.0–16.8) 3.5 (0.9–4.0) 0.37 3.5 (0.6–17.5) 3.5 (1.5–6.3) 0.57
Central line
infection
64.7 % 85.7 % 0.38 68.8 % 66.7 % 0.99 71.4 % 70.0 % 0.99
Bacteremia at 48 h 17.6 % 0.0 % 0.53 12.5 % 12.5 % 0.99 14.3 % 10.0 % 0.99
MDR 5.9 % 42.9 % 0.027 18.8 % 12.5 % 0.80 21.4 % 10.0 % 0.48
ICU 35.3 % 28.6 % 0.76 37.5 % 25.0 % 0.56 42.9 % 20.0 % 0.26
Abx in past 30 days 47.1 % 28.6 % 0.43 37.5 % 50.0 % 0.67 42.9 % 40.0 % 0.99
Immuno-suppressant 29.4 % 71.4 % 0.06 43.8 % 37.5 % 0.78 42.9 % 40.0 % 0.99
Length of stay (days) 17.0 (4.5–80.0) 5.0 (3.0–20.0) 0.21 0.99 18.5 (4.3–63.3) 5.0 (3.3–35) 0.32 11.0 (3.0–97.5) 10.5 (4.5–27.3) 0.92
SHS exposure 23.5 % 28.6 % 0.99 34.1 % 53.5 % 0.13 28.6 % 20.0 % 0.99
GER 35.3 % 28.6 % 43.8 % 12.5 % 0.14 35.7 % 30.0 % 0.99
Data are expressed as a percentage of cases with medians and ranges
Abx antibiotic use in 30 days prior to infection; GER gastroesophageal reflux; ICU Intensive care unit care required; MDR multi-drug resistance with isolates non-susceptible
to≥ 1 antimicrobial agent in ≥ 3 antimicrobial categories; SHS secondhand smoke
Fig. 2 Bacterial isolate characteristics. a Individual isolate results of biofilm and twitching and surface-associated motility assays with grouping by species.
The level of biofilm formation was determined by measuring the absorbance at 595 nm post crystal violet staining. Error bars represent the standard
deviation of the mean of three independent experiments. Twitching and surface-associated motility are characterized as positive or negative
based on experimental methods. All experiments performed in triplicate. Strains are designated as: “b” = baumannii, “p” = pittii, “n” = nosocomialis,
“c” = calcoaceticus, two strains are undesignated. b Box and whiskers plot demonstrating sum of median biofilm production with minimum and
maximum error bars for A. pittii and A. baumannii strains from Fig. 2a, P value =0.018
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recent A. pittii strains did display both twitching and
surface-associated motility phenotypes, indicating the
likely expression of a functional type IV pilus as well as
changing local population dynamics. Additionally, A pittii
isolates averaged more robust biofilm production when
compared to A. baumannii isolates, indicating another po-
tential pathogenic mechanism for the increasing A pittii
prevalence. However, laboratory biofilm studies may not
reflect human in vivo biofilm formation, therefore further
studies are warranted in this area for the future.
Despite previous reports of high mortality associated
with antibiotic resistant Acinetobacter strains [5, 7], in
our sampling only 2 out of 24 cases were associated with
patient deaths. Notably, both deaths were from A. pittii,
again in contrast with the existing pediatric literature on
A. baumannii-associated mortality, and the antibiotic
resistance patterns observed. We postulate that one dif-
ference in the overall low mortality rates could be the
relative sensitivity to the aminoglycoside antibiotics
coupled with prompt administration, as this class of
antibiotic was utilized in the first 48 h of a suspected in-
fection in half of the reported cases. There was also a
low prevalence of MDR strains. Both of these factors
may have contributed to the fact that nearly 80 % of the
strains were cleared from the systemic circulation within
48 h of initiating antibiotics. Persistent bacteremia was
noted to be associated with biofilm-producing isolates,
which is of importance when assessing therapeutic op-
tions for persistent Acinetobacter infections. Addition-
ally, compared to other reported pediatric Acinetobacter
infections, the isolated strains demonstrated lower over-
all morbidity as reflected by fewer intensive care require-
ments and less multiple organ involvement. Much of the
published pediatric literature focuses on neonatal intensive
care units with multiple Acinetobacter infections [3, 8–12].
However, in our sample, the median age was 3.5 years with
no reported neonatal infections. We were unable to assess
for the role of existing institutional infection control
bundles in preventing ICU-associated infections during
this retrospective study. Therefore, continued work will
be needed to address potential epidemiologic factors
associated with pediatric Acinetobacter infections in the
United States.
Other species of Acinetobacter are increasingly recog-
nized to cause disease in humans such as A. bereziniae
[26], further supporting the assumption that improved
species identification of Acinetobacter infections may be
needed to accurately follow emerging infectious trends
from an epidemiologic level. These results further high-
light the medical relevance of the Acinetobacter genus as
whole, where an encounter between a patient with a
compromised immune system and a species of Acineto-
bacter, regardless of its characterized pathogenicity can
result in infection.
We acknowledge that this study has several limita-
tions. First, the study was retrospective in nature, there-
fore limiting the availability of some clinical information.
Second, the small sample size, 5-year time frame, and
single-center setting limits the generalizability of the
findings and analysis of isolate phenotypic characteristics
in relation to clinical outcomes. However, the samples
may be more representative of U.S. pediatric academic
centers than previous reports from developing countries.
Finally, the clinical laboratory did not report antibiotic
susceptibilities for all classes of antibiotics for the four
isolates obtained in the first year of the study.
Conclusions
In summary, knowledge of pediatric Acinetobacter infec-
tions has been limited to date by clinical laboratory iden-
tification methods, which may presume Acinetobacter
induced infections to be caused by A. baumannii. A. pittii
was discovered to be the dominant local clinical strain ex-
pressing a variety of phenotypic characteristics including 2
fatalities. The isolated strains in this study had limited over-
all long-term morbidity or mortality in a pediatric popula-
tion, but the occurrence of more MDR strains in the future
is a distinct possibility, leading to the need for continued
research and accurate species identification.
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